Company Profile
Monopar Stock Price, News & Analysis
- Ticker:
- MNPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
114.46 USD (-1.62%)
Close
Last updated: August 11, 2026
410M USD
Market cap
Why the stock is moving
The latest monitored company update is “Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates.” The corresponding closing-price reaction is not yet available.
Company overview
Business overview
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
Geographic Base and Sector Classification
Monopar is headquartered in the United States and listed on NASDAQ. It sits in small-cap specialty biopharma.
Business Model Characteristics
The company depends on clinical progress, strategic prioritization, and capital management across a narrow program set. Investors typically watch proof-of-concept data and financing runway.
Position Within the Biotechnology Landscape
Monopar occupies a catalyst-sensitive niche within biotech. The stock is driven by whether its focused development approach can produce clear differentiated value.
Future catalysts
- What matters most for Monopar from here is ALXN1840 and tiomolibdate choline. That matters because the company is now talking about NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at.... That is the piece most likely to shape sentiment in the near term.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Monopar (MNPR)?
Monopar (MNPR) most recently closed at 114.46 USD, a -1.62% move versus the previous session.
What is the market cap of Monopar (MNPR)?
Monopar currently has a market capitalization of 410M USD on BioPharmSignal.
What does Monopar do?
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
On which exchange is MNPR stock listed?
Monopar (MNPR) is associated with NASDAQ, United States, Biopharma.
What is Monopar?
What matters most for Monopar from here is ALXN1840 and tiomolibdate choline.
Which conditions is Monopar targeting with Monopar?
Monopar is associated with oncology, rare disease based on its company overview and current catalyst commentary.
How does Monopar describe recent progress with Monopar?
What matters most for Monopar from here is ALXN1840 and tiomolibdate choline.
What is Therapeutics?
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications.